Navigation Links
ViroPharma To Participate In Several June Healthcare Investor Conferences
Date:5/31/2013

EXTON, Pa., May 31, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano , president and chief executive officer of ViroPharma, will present at the Jefferies 2013 Healthcare Conference at 9:30 AM ET on Wednesday June 5, 2013.  The conference is being held in New York City.

ViroPharma also announced that Charles Rowland , vice president and chief financial officer of ViroPharma, will present at the Goldman Sachs 34th Annual Global Healthcare Conference at 4:00 PM PT (7:00 PM ET) on Tuesday, June 11, 2013.  The conference is being held in Rancho Palos Verdes, CA.

Mr. Milano also will be presenting at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 2:20 PM ET on Tuesday, June 18, 2013.  The conference is being held in Boston, MA.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma er stolt over at bakke op om HAE-dag :-) 2013 og vi hjælper HAE-patienter med at fylde verden med smil
2. ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
4. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
5. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
6. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
7. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
8. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
10. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
11. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... With over 60 ... walk, the demand for a sustainable product to aid in the rehabilitation process has ... in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, which come courtesy of leaders in the nursing ... within the industry, from leading advocates and associations—namely Abilene Christian University. , As ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... name in the pharmaceutical, medical and food industries. Aside from its GMP accreditation, ... (SIC), providing proof of successfully certified products, services and staff. , Validation Center ...
Breaking Medicine News(10 mins):